Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cysti... ( MARIETTA Ga. Oct. 9 /- Solvay Pharmac...)

HOME >> MEDICINE >> TECHNOLOGY

Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cystic Fibrosis

Date:10/9/2009

MARIETTA, Ga., Oct. 9 /PRNewswire/ -- Solvay Pharmaceuticals, Inc. announced today that Phase III data published in the Journal of Cystic Fibrosis showed that CREON® (pancrelipase) Delayed-Release Capsules, the most prescribed pancreatic enzyme replacement therapy (PERT) in the United States, significantly improves a key measure of fat absorption in patients with CF who suffer from exocrine pancreatic insufficiency (EPI). EPI is a condition resulting from a deficiency in the production and/or secretion of pancreatic enzymes that are necessary to digest nutrients in food and, if untreated, can lead to poor growth, poor weight gain and failure to thrive in children with CF.

According to the study results, patients with CF and confirmed EPI had an improved coefficient of fat absorption (CFA) during treatment with CREON® compared to treatment with placebo. CFA is calculated based on measures of fat ingestion and fat excretion; assessing the CFA of a patient is a way to measure the absorption of fat as a percentage of fat intake in patients being tested for EPI. The trial reached statistical significance on its primary endpoint, which was CFA.

"These study results demonstrate that CREON® is effective in decreasing the maldigestion and malabsorption associated with pancreatic insufficiency in patients with cystic fibrosis," said Bruce C. Trapnell, MD, Professor of Medicine and Pediatrics at the University of Cincinnati and Cincinnati Children's Hospital Medical Center. "Patients enrolled in this study had poor fat absorption without treatment, which is commonly associated with uncomfortable gastrointestinal symptoms and severe malnutrition. In addition to the impressive increase in fat absorption demonstrated in these individuals, the secondary outcomes of the study have important implications for those involved in the care of these patients."

CREON® was approved by the Food and Drug Administration (F
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Endo Pharmaceuticals to Announce Third Quarter 2009 Financial Results on October 29, 2009
2. CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010
3. Accuray Incorporated to Report Financial Results for First Quarter of Fiscal 2010
4. NuVasive Announces Conference Call and Webcast of Third Quarter 2009 Results
5. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
6. TOPICA Announces Positive Phase 2 Clinical Results for Luliconazole, a Potent Topical Antifungal
7. Robbins & Myers Announces Fourth Quarter and Full Year 2009 Results
8. Cantel Medical Corp. To Hold Conference Call To Discuss Fourth Quarter and Fiscal 2009 Results
9. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2009 Results
10. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2009 Financial Results
11. Immucor Announces Fiscal First Quarter Results

Post Your Comments:

(Date:12/16/2009)... 17 Cell Therapeutics, Inc. (CTI) ... on February 10, 2010 the U.S. Food ... (ODAC) will review the New Drug Application ... relapsed/refractory aggressive non-Hodgkin,s lymphoma (NHL). ODAC is ... data concerning the efficacy and safety of ...

(Date:12/16/2009)... Medlytix, a national healthcare consulting firm, ... half-billion dollar milestone - the total amount of ... financial assistance to more than a half-million patients ... classifying charity care - in less than two ... hospitals enhanced their bottom lines and still were ...

(Date:12/16/2009)... Dec. 16 Ethicon, Inc., a Johnson ... and a worldwide leader in surgical care, and ... dedicated to designing, developing and commercializing devices that ... (ENT), today announced a definitive merger agreement whereby ... for approximately $785 million net of estimated cash ...

Breaking Medicine Technology:Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 2 Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 3 Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 4 Healthcare Scoring System Allows Hospitals To Increase Charity Care 2 Healthcare Scoring System Allows Hospitals To Increase Charity Care 3 Healthcare Scoring System Allows Hospitals To Increase Charity Care 4 Ethicon Announces Definitive Agreement to Acquire Acclarent 2 Ethicon Announces Definitive Agreement to Acquire Acclarent 3 Ethicon Announces Definitive Agreement to Acquire Acclarent 4 ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 1 ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 2 ECRI Institute Releases Roadmap to the Evidence on Finasteride for Prevention of Prostate Cancer 3A New Hotline Report to Aid Healthcare Decision Make 6429 3 Biologists discover bacterial defense mechanism against aggressive oxygen 10837 1 Biologists discover bacterial defense mechanism against aggressive oxygen 10837 2 Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 1 Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 2 Lehigh receives grant to reduce cost of carbon capture at coal fired power plants 10833 3

[0] Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010 [0] Healthcare Scoring System Allows Hospitals To Increase Charity Care [0] Ethicon Announces Definitive Agreement to Acquire Acclarent

... June 25 Vical Incorporated,(Nasdaq: VICL ) ... milestones under a three-year, $6.0 million grant awarded ... a DNA vaccine manufacturing,process with the potential to ... of days., The RapidResponse(TM) system is designed ...

... Initiates a Phase I/II Study of Zalutumumab in Combination, ... Head and Neck Cancer., COPENHAGEN, June 24 ... Phase I/II study of zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy ... study will include a maximum of 36,patients who are ...

Other Medicine Technology:Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 2 Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 3 Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 4 Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH 5 Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2 Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3

Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer

(Date:12/17/2009)... CDC,s Morbidity and Mortality Weekly Report (MMWR) released ... epidemiologists has decreased steadily since 2004, with a ... was also a substantial decrease in core epidemiology ... for bioterrorism and emergency response. For ... substance abuse, and oral health, basic epidemiology capacity ...

(Date:12/17/2009)... Good Samaritan Hospital is changing the way women manage ... of the Good Samaritan Hospital Women,s Center For Bladder ... help treat two common medical problems - lack of ... uterus or rectum (pelvic organ prolapse). Three out of ... one out of three may experience pelvic organ prolapse, ...

(Date:12/17/2009)... OAKLAND, Calif., Dec. 17 Today, SEIU ... that Alameda County In-Home Supportive Service (IHSS) providers ... contract with the County that adds multiple layers ... and benefit levels, as well as granting additional ... joining the Governor,s desire to slash homecare provider ...

(Date:12/17/2009)... WALTHAM, MA Brandeis University selected Jay and Maureen Neitz, ... the use of gene therapy to treat vision disorders, ... Award in Vision Sciences. , The award is funded ... a gift from Brandeis graduates Jay Pepose ,75 and ... supports graduate research fellowships in vision science. , The ...

(Date:12/17/2009)... hospital clients Rutherford Hospital Inc. (Rutherfordton, N.C.), a management ... management client since 1992, were recently recognized as top-ranked ... ... Brentwood, Tenn. (PRWEB) ... Rutherford Hospital Inc. (Rutherfordton, N.C.), a management client since ...

Breaking Medicine News(10 mins):Health News:CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking 2 Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 2 Health News:Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health 3 Health News:New Alameda County IHSS Contract Sends Clear Message to Elected Leaders That Homecare Program Must Remain a California Priority 2 Health News:Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis 2 Health News:QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value 2

[0] CSTE National Assessment Finds Critical Public Health Disease Surveillance Capacity Lacking [0] Good Samaritan Hospital Launches Women's Center For Bladder & Pelvic Health [0] New Alameda County IHSS Contract Sends Clear Message to Elected Leaders That Homecare Program Must Remain a California Priority [0] Vision researchers Jay and Maureen Neitz to receive first Pepose Award from Brandeis [0] QHR Client Hospitals in North Carolina, Michigan Lauded for Providing Community Value

... The Procter & Gamble,Company (NYSE: PG ... New York City,beginning at 8:30 a.m. Eastern Time. ... and the Company,s executive management team will,provide a review ... growth opportunities. , ...

... commissioned insurance sales agents in Canada are on the rise ... ... recent reports by Statistics Canada that unemployment is growing and consumer ... supplemental insurance, reports job opportunities for commissioned insurance sales agents in ...

... ... Panama City, FL (PRWEB) December 11, 2008 -- iSirona®, an ... that Peter Witonsky has been named president and chief sales officer. ... over the past 12 months. Company founder and former President Dave ...

... of Electronic Medical Record and practice billing solutions for the healthcare ... company as Chief Commercial Officer. Flormann brings 25 years of ... business and market development to Glenwood Systems. , ... ...

... OH, December 11, 2008 -- More than half a million ... and preterm births are on the rise. Late preterm ... (approximately 4 to 6 weeks before the mother,s due date), ... the large number of affected babies, many people are unaware ...

... ACEL ) today reported its financial results for the first quarter ... company recorded a net loss of approximately $2.8 million, or $0.06 ... Oct. 31., compared to a net loss of $2.7 million, or ... of fiscal 2008. Research and development expenses increased by approximately ...

Other Medicine News:Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 2 Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 3 Health News:P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting 4 Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 2 Health News:Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy 3 Health News:iSirona Announces New President and Chief Sales Officer 2 Health News:Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer 2 Health News:Late preterm births present serious risks to newborns 2 Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 2 Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 3 Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 4 Health News:Alfacell Reports Financial Results for First Quarter of Fiscal 2009 5

P&G To Share Confidence in Long-Term Strategies and Goals at 2008 Analyst Meeting Insurance Job Opportunities Rise in Canada in Spite of Challenging Economy iSirona Announces New President and Chief Sales Officer Glenwood Systems, LLC Appoints Ron Flormann Chief Commercial Officer Late preterm births present serious risks to newborns Alfacell Reports Financial Results for First Quarter of Fiscal 2009

Enzymatic Clearance assay for the in vitro quantitative determination of HDL-cholesterol in human serum and plasma....

Immunoturbidimetric assay for the quantitative in vitro determination of Lipoprotein (a) in human serum or plasma...

Medicine Products:

HDL-Cholesterol (AHDL)Lipid Control Level 3 Lipid Control Level 1 Lipoprotein (a) Calibrator Series

Results Published In Journal of Cystic Fibrosis Confirm CREON(R) (pancrelipase) Delayed-Release Capsules Improves Fat Absorption in Patients With Cysti...( MARIETTA Ga. Oct. 9 /- Solvay Pharmac...),Health